Shenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
1
Shenzhen Accord Pharmaceutical Co., Ltd.
The First Quarterly Report 2009（full text）
§1. Important Notice
1.1 The board of directors, the supervisory committee, all directors and supervisors and the senior executive of Shenzhen Accord
Pharmaceutical Co., Ltd. (hereinafter referred to as the Company) hereby confirm that there are no fictitious statements, serious misleading or
important omissions information carried in this report, and shall take all responsibilities, jointly and severally, for the truthfulness, accuracy and
completeness of the whole contents.
1.2 No director, supervisor and senior executive of the Company stated any objection for the correctness, accuracy and completeness of
the contents in this report.
1.3 All directors attended the voting meeting of the board of directors for examining the quarterly report by communication.
1.4 The first quarterly financial report of 2009 has not been audited by the public accountants.
1.5 Chairman of the Board Mr. Shi Jinming and General Manager Mr. Yan Zhigang, CFO Mr. Wei Pingxiao, and Manager of the Financial
Department Mr. Chi Guoguang hereby confirm that the Financial Report of the First Quarter Report 2009 is true and complete.
§2. Company Profile
2.1 Main Accounting Data and Financial Indexes:
Unit: RMB
At the end of the report period
At the end of the last year
Changes of increase/decrease (%)
Total assets
4,273,371,625.45
3,683,974,196.77
16.00%
Equity attributable to owners of the parent company
671,056,874.78
627,986,713.06
6.86%
Share capital
288,149,400.00
288,149,400.00
0.00%
Net asset per share attributable to owners of the parent company
2.329
2.179
6.88%
In the report period
The same period of last year
Changes of increase/decrease (%)
Total operating income
2,244,765,347.92
1,846,488,889.58
21.57%
Net profit attributable to owners of the parent company
43,070,161.72
38,013,002.85
13.30%
Net cash flow arising from operating activities
67,253,449.21
-55,114,839.48
222.02%
Net cash flow arising from operating activities per share
0.233
-0.191
221.99%
Basic earnings per share
0.149
0.132
12.88%
Diluted earnings per share
0.149
0.132
12.88%
Return on equity
6.42%
7.21%
-0.79%
Return on equity after deducting the non-recurring losses and gains
6.36%
6.95%
-0.59%
Items of non-recurring gains and losses
Amount in year-begin to the end of report periodShenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
2
Gains and losses from the disposal of non-current asset
-28,082.81
Governmental subsidy reckoned into current gains and losses, while closely related with the business of the Company, excluding the fixed-
amount or fixed-proportion governmental subsidy according to the unified national standard
500,000.00
Other non-operating income and expenditure beside for the above items
-9,281.64
Impact on income tax
-66,446.14
Total
396,189.41
Explanations on items of non-recurring gains and losses
In the report period, gains and losses from the disposal of non-current asset was the gains/losses from the disposal of fixed assets; the
governmental subsidy reckoned into current gains and losses was the wholly-owned subsidiary of the Company Shenzhen--Zhijun
Pharmaceutical Co., Ltd. obtained subsidy RMB 500,000 from the local government.
2.2 Total number of shareholders at the end of the report period and shares held by the top ten shareholders with unrestricted conditions
Unit: Share
Total number of shareholders
at the end of report period
21,307
Particulars about the shares held by the top ten tradable shareholders with unrestricted conditions
Full Name of shareholder
Amount of tradable shares with unrestricted conditions held at the end of report period
Type of shares
SINOPHARM MEDICINE HOLDING CO., LTD.
26,494,102
RMB common share
BANK OF CHINA－FRANKLIN TEMPLETON SEALAND POTENTIAL COMBINATION FUND
11,387,141
RMB common share
CHINA CONSTRUCTION BANK－HUAAN HONGLI STOCK FUND
5,108,478
RMB common share
CHINA INDUSTRIAL AND COMMERCIAL BANK－BOSHI SELECTIVE STOCK FUND
4,963,365
RMB common share
CHINA INDUSTRIAL AND COMMERCIAL BANK－GUANGFA JUFENG STOCK FUND
4,912,540
RMB common share
BANK OF CHINA－AIG-HUATAI PROSPEROUS CHINA EQUITY FUND
4,899,808
RMB common share
BANK OF CHINA－CHINA MERCHANTS
4,882,572 PIONEER FUND
RMB common share
BANK OF CHINA－DACHENG WEALTH MANAGEMENT 2020
4,747,700 LIFECYCLE FUND
RMB common share
CHINA INDUSTRIAL AND COMMERCIAL BANK－CHINA MERCHANTS
4,406,026 CORE VALUE MIXED FUND
RMB common share
CHINA INDUSTRIAL AND COMMERCIAL BANK－BOC CONTINUOUS GROWTH FUND
4,375,188
RMB common shareShenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
3
§3. Significant events
3.1 Particulars about material changes in items of main accounting statement and financial index, and explanations of reasons
√Applicable □Inapplicable
1. Monetary capital as of period-end increased RMB 168.38 million over that of period-begin, which was
mainly due to that: (1)sales scale of the Company expanded in the report period (2) consolidated Suzhou Zhijun
Wanqing Pharmaceutical Co., Ltd. (hereinafter referred to Zhijun Wanqing)
2. Other account receivable as of period-end increased RMB 13.63 million over that of period-begin, which
was mainly due to that: (1) consolidated Suzhou Zhijun Wanqing; (2) underlying subsidiary of the Company-
Sinopharm
3. Intangible assets as of period-end increased RMB 52.36 million over that of period-begin, which was
mainly due to that: consolidated Zhijun Wanqing. Medicine Holding Guangzhou Co., Ltd increased account
receivable from Sino-American Shanghai Squibb Pharmaceuticals Ltd. as sales allowance.
4. Short-term loans as of period-end increased RMB 261.52 million over that of period-begin, which was
mainly due to that: (1) consolidated Suzhou Zhijun Wanqing; (2) in order to satisfy equity purchase and
expansion of sales scale of the Company, short-term loans and discounted notes were needed to increase.
5. Account received in advance as of period-end increased RMB 17.02 million over that of period-begin,
which was mainly due to that the underlying subsidiary of the Company-Shenzhen Zhijun Pharmaceuticals Co., Ltd.
(hereinafter referred to as Zhijun Pharmaceuticals) received a great growth in sales over the same period of
last year.
6. Wages payable as of period-end decreased RMB 41.58 million over that of period-begin, which was mainly
due to that part performance-related salary and annual bonus withdrew in 2008 have been granted in 2009.
7. Tax payable as of period-end increased RMB 25.01 million over that of period-begin, which was mainly due
to that the sales income Company increased greatly over the same period of last year which led more or less
increase in VAT and enterprise income tax.
8. Interest payable as of period-end decreased RMB 0.63 million over that of period-begin, which was mainly
due to that the Company poured more efforts in attempering internal capital and thus saved capital cost.
9. Dividend payable as of period-end increased RMB 2 million over that of period-begin, which was mainly
due to consolidation of Zhijun Wanqing.
10. Minor shareholders’ equity as of period-end increased RMB 33.92 million over that of period-begin,
which was mainly due to that 25% minor shareholders’ equity was increased by consolidation of Zhijun Wanqing.
11. Business tax and surcharge as of this report period increased RMB 0.73 million over the same period of
last year, which was mainly due to that great growth in sales income of underlying subsidiary of the Company-
Zhijun Pharmaceuticals caused increase in city construction tax, etc.
12. Sales expense as of this report period increased RMB 17.49 million over the same period of last year,
which was mainly due to that: (1) in order to enlarge market share, Zhijun Pharmaceuticals poured more efforts
in sales, expenses for market development and propaganda increased over the same period of last year. Besides,
consultation and inspection fee for international authentication were newly increased; (2) in order to meet
demand for sales expansion, more new employees would be engaged, and meanwhile, growth of working-age-related
salary and performance-related salary had increases. .
13. Financial expense as of this report period decreased RMB 4.11 million over the same period of last
year, which was mainly due to great drop in interest rate of bank loans and discount rate for notes.
14. Non-operating income as of this report period decreased RMB 1.27 million over the same periodShenzhen
Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
4
of last year, which was mainly due to that underlying subsidiary of the Company-Zhijun Pharmaceuticals
received a decrease in governmental subsidy over the same period of last year.
15. Income tax expense as of this report period increased RMB 8 million over the same period of last year,
which was mainly due to that profit of this report period increased over the same period of last year and
transfer of internal equity.
16. Tax return received in this report period increased RMB 0.22 million over the same period of last year,
which was mainly due to that the underlying subsidiary of the Company-Shenzhen Zhijun Medicine Trade Co., Ltd.
increased export sales this year.
17. Net cash flow arising from operating activities in this report period increased RMB 122.37 million over
the same period of last year, which was mainly due to that the Company and its underlying subsidiaries not only
received stable growth in sales income, but also strengthened efforts in calling back sales accounts.
18. Cash received from investment income in this report period decreased RMB 0.23 million over the same
period of last year, which was mainly due to that the affiliated company did not have dividend in this report
period.
19. Net cash received from disposal of fixed assets, intangible assets and other long-term assets in this
report period decreased RMB 1.13 million over the same period of last year; cash paid for purchase of fixed
assets, intangible assets and other long-term assets in this report period decreased RMB 1.64 million over the
same period of last year. Main reason for the changes were that the underlying subsidiary of the Company-
Zhijun Pharmaceuticals disposed many fixed assets for relocating its workshop and purchased many fixed assets
for capacity expansion in the last report period.
20. Net cash flow arising from investment activities in this report period decreased RMB 60.93 million over
the same period of last year, which was mainly due to equity account were paid for purchasing Zhijun Wanqing
and Dongguan Accord Medicine Co., Ltd.
21. Cash received from other activities relevant to financing in this report period increased RMB 102.98
million over the same period of last year, w, which was mainly due to financing of the Company and its
underlying subsidiaries by notes discount.
22. Cash paid for repaying debt in this report period increased RMB 19.98 million over the same period of
last year, which was mainly due to the Company increased repayment of short-term loans to banks over the same
period of last year.
23. Cash paid for other activities relevant to financing in this report period increased RMB 28.24 million
over the same period of last year, which was mainly due to that the Company provided borrowing to Zhijun
Wanqing.
3.2 Analysis and explanation of significant events and their influence and solutions
□Applicable √Inapplicable
3.3 Implementations of commitments by the Company, shareholders and actual controller
√Applicable □Inapplicable
Commitments
Content of commitments
Implementation
Commitments for Share Merger Reform
(1) Not selling original non-tradable equities through stock exchange in 24 months from the day they become
tradable. (2) Original non-tradable equities sold after the 24 months through stock exchange take up no more
than 10% of the Company’s total shares in the following 12 months, and the price
ImplementingShenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
5
is no lower than 110% of the stock weighted average price, that is RMB5.05, of the 30 trading days before
Accord Pharmaceutical’s Board of Directors publish the Reform Plan (from the day of implementing Non-tradable
Shares Reform to the day when Sinopharm Medicine Holding sells equities, Ex Warrant/Ex Dividend on the price
will be implemented if dividend, allotment or transferring of public capital to equity and so on happens ).
Commitments on share restriction for trading
Inapplicable
Inapplicable
Commitments made in Acquisition Report or Reports on Change in Interests
Inapplicable
Inapplicable
Commitments made in Material Assets Reorganization
Inapplicable
Inapplicable
Commitments made in issuing
Inapplicable
Inapplicable
Other commitments (including additional commitments)
Inapplicable
Inapplicable
3.4 Estimation of accumulative net profit from the beginning of the year to the end of next report period
to be loss probably or the warning of its material change compared with the corresponding period of the last
year and explanation of reason
□Applicable √Inapplicable
3.5 Other significant events which need explanations
3.5.1 Particulars about securities investment
□Applicable √Inapplicable
3.5.2 Registration form for receiving research, communication and interview in the report period.
The received date
The received place
The received way
The received parties
Contents discussed and materials supplied
Feb. 10, 2009
Conference room of the Company
Spot research and attended the Shareholders’ General Meeting
Franklin Templeton Sealand Fund Management Co., Ltd
Attended the 1st Extraordinary Shareholders’ General Meeting 2009 of the Company, discussed the proposals,
the introduction to the operations of the Company, and replies to industry development.
Hua An Fund Management Co., Ltd
China Merchants Fund Management Co., Ltd.
China Southern Fund Management Co., Ltd.
Da Cheng Fund Management Co., Ltd.
UBS SDIC FUND MANAGEMENT CO., LTD.Shenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
6
Guoxin Securities Co., Ltd.
Changjiang Securities Co., Ltd.
3.5.3 Particulars about the explanations on other significant events
√Applicable □Inapplicable
1. On August 28, 2008, the Company purchased the enterprise—Guangxi Accord Pharmaceutical Co., Ltd. under
the common control, in accordance with the regulations of No.20 of Enterprise Accounting Standards-Enterprises
Merger, adjustments were made in comparative statement in March 2008, the retroactive adjustments included
decrease the total amount of profit and net profit attributable to owners of the parent company both with the
amount of RMB 11,356; and increase the equity attributable to owners of the parent company and total assets
both with the amount of RMB4,991,622.49.
2. In Jan. 2009, the Company accomplished the 100 percent equity purchase on Dongguan Accord Pharmaceutical
Co., Ltd.(with the original name of Dongguan Dongfeng TCM Co., Ltd.).
3. In March 2009, the Company accomplished the 75 percent equity purchase on Suzhou Wanqing Pharmaceutical
Co., Ltd.
§4. Appendix
4.1 Balance sheet
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. March 31, 2009 Unit: RMB
Items
Balance at period-end
Balance at year-begin
Merger
Parent Company
Merger
Parent Company
Current assets:
Monetary funds
513,643,157.76
136,036,810.88
345,259,516.47
62,369,583.65
Settlement provisions
Capital lent
Transaction finance asset
Notes receivable
249,810,241.89
2,365,677.07
221,876,250.45
254,500.00
Accounts receivable
1,888,743,718.73
280,364,007.38
1,726,711,922.82
243,301,803.10
Accounts paid in advance
32,735,955.73
5,992,346.01
40,034,923.45
4,919,683.46
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance receivable
Interest receivable
103,515.25
Dividend receivable
Other receivables
46,235,733.90
202,605,385.85
32,606,307.59
242,415,823.08
Purchase restituted finance asset
Inventories
790,654,408.19
78,160,538.15
735,661,642.08
94,249,578.90
Non-current asset due within one year
Other current assetsShenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
7
Total current assets
3,521,926,731.45
705,524,765.34
3,102,150,562.86
647,510,972.19
Non-current assets:
Granted loans and advances
Finance asset available for sales
Held-to-maturity securities
Long-term account receivable
Long-term equity investment
72,393,249.89
617,623,739.08
69,578,981.80
323,756,562.92
Investment property
22,566,619.72
2,102,689.92
22,848,031.69
2,140,353.75
Fixed assets
448,356,098.72
35,920,264.50
374,870,446.95
36,732,350.96
Construction in progress
21,975,681.02
253,886.24
18,756,982.97
253,886.24
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets
109,969,174.52
30,316,198.16
57,607,282.99
30,622,772.31
Expense on Research and Development
235,375.01
Goodwill
34,184,991.76
Long-term expenses to be apportioned
16,967,996.68
122,129.51
16,414,181.91
276,057.82
Deferred income tax asset
7,912,121.52
7,869,895.86
Other non-current asset
16,883,585.16
13,877,829.74
Total non-current asset
751,444,894.00
686,338,907.41
581,823,633.91
393,781,984.00
Total assets
4,273,371,625.45
1,391,863,672.75
3,683,974,196.77
1,041,292,956.19
Current liabilities:
Short-term loans
640,469,790.48
156,999,533.74
378,948,301.38
80,171,729.25
Loan from central bank
Absorbing deposit and interbank deposit
Capital borrowed
Transaction financial liabilities
Notes payable
814,786,801.93
195,453,484.07
791,513,252.27
129,298,292.87
Accounts payable
1,502,660,238.64
265,278,144.03
1,357,026,915.55
268,335,731.42
Accounts received in advance
35,509,004.89
26,037.86
18,487,835.55
4,626,342.73
Selling financial asset of repurchase
Commission charge and commission payable
Wage payable
32,615,272.07
7,009,680.22
74,195,821.61
14,678,407.64
Taxes payable
39,394,140.86
3,787,261.14
14,379,964.47
-963,780.92
Interest payable
114,947.01
742,393.70
39,700.00Shenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
8
Dividend payable
5,746,270.05
3,746,270.05
Other accounts payable
351,725,080.46
356,652,676.98
271,731,949.89
119,209,791.88
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Non-current liabilities due within 1 year
57,720,000.00
57,720,000.00
Other current liabilities
Total current liabilities
3,480,741,546.39
985,206,818.04
2,968,492,704.47
615,396,214.87
Non-current liabilities:
Long-term loans
30,000,000.00
30,000,000.00
Bonds payable
Long-term account payable
49,950.60
51,261.00
Special accounts payable
960,000.00
800,000.00
800,000.00
800,000.00
Projected liabilities
Deferred income tax liabilities
12,174,180.87
12,174,180.87
Other non-current liabilities
23,085,874.07
23,085,874.07
Total non-current liabilities
66,270,005.54
800,000.00
66,111,315.94
800,000.00
Total liabilities
3,547,011,551.93
986,006,818.04
3,034,604,020.41
616,196,214.87
Owner’s equity (or shareholders’ equity):
Paid-in capital (or share capital)
288,149,400.00
288,149,400.00
288,149,400.00
288,149,400.00
Capital public reserve
5,055,838.57
2,508,769.94
5,055,838.57
2,508,769.94
Less: Inventory shares
Surplus public reserve
9,303,064.31
9,303,064.31
12,781,301.82
Provision of general risk
Retained profit
368,548,571.90
115,198,684.77
325,478,410.18
121,657,269.56
Balance difference of foreign currency translation
Total owner’s equity attributable to parent company
671,056,874.78
405,856,854.71
627,986,713.06
425,096,741.32
Minority interests
55,303,198.74
21,383,463.30
Total owner’s equity
726,360,073.52
405,856,854.71
649,370,176.36
425,096,741.32
Total liabilities and owner’s equity
4,273,371,625.45
1,391,863,672.75
3,683,974,196.77
1,041,292,956.19
4.2 Profit statement
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Mar., 2009 Unit: RMB
Items
Amount in this period
Amount in last period
Merger
Parent Company
Merger
Parent Company
I. Total operating income
2,244,765,347.92
345,724,949.43
1,846,488,889.58
310,499,442.93Shenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
9
Including: Operating income
2,244,765,347.92
345,724,949.43
1,846,488,889.58
310,499,442.93
Interest income
Insurance gained
Commission charge and commission income
II. Total operating cost
2,187,712,939.29
342,943,174.87
1,802,270,513.75
309,944,834.16
Including: Operating cost
2,059,715,560.24
329,553,793.05
1,693,071,778.77
294,874,588.78
Interest expense
Commission charge and commission expense
Cash surrender value
Net amount of expense of compensation
Net amount of withdrawal of insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras
2,925,909.64
56,246.11
2,199,570.23
39,751.95
Sales expenses
74,691,577.38
8,133,355.06
57,202,134.90
7,658,632.58
Administration expenses
42,131,372.53
5,317,889.39
38,197,888.30
8,030,967.71
Financial expenses
8,104,806.10
-118,108.74
12,212,865.21
296,061.25
Losses of devaluation of asset
143,713.40
-613,723.66
-955,168.11
Add: Changing income of fair value(Loss is listed with “-”)
Investment income (Loss is listed with “-”)
2,814,268.09
-526,193.43
2,976,228.64
295,611.98
Including: Investment income on affiliated company and joint venture
2,814,268.09
-526,193.43
2,976,228.64
295,611.98
Exchange income (Loss is listed with “-”)
III. Operating profit (Loss is listed with “-”)
59,866,676.72
2,255,581.13
47,194,604.47
850,220.75
Add: Non-operating income
537,260.53
10,435.14
1,809,322.70
4,199.30
Less: Non-operating expense
74,624.98
10,128.50
167,330.55
3,908.31
Including: Disposal loss of non-current asset
53,563.15
7,843.33
3,908.31
IV. Total Profit (Loss is listed with “-”)
60,329,312.27
2,255,887.77
48,836,596.62
850,511.74
Less: Income tax
16,694,417.86
8,695,463.44
V. Net profit (Net loss is listed with “-”)
43,634,894.41
2,255,887.77
40,141,133.18
850,511.74
Net profit attributable to owner’s equity of parent company
43,070,161.72
2,255,887.77
38,013,002.85
850,511.74
Minority shareholders’ gains and losses
564,732.69
2,128,130.33Shenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
10
VI. Earnings per share
i. Basic earnings per share
0.149
0.132
ii. Diluted earnings per share
0.149
0.132
4.3 Cash flow statement
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Mar., 2009 Unit: RMB
Items
Amount in this period
Amount in last period
Merger
Parent Company
Merger
Parent Company
I. Cash flows arising from operating activities:
Cash received from selling commodities and providing labor services
2,364,256,357.44
369,845,596.20
1,842,559,540.10
317,262,748.18
Net increase of customer deposit and interbank deposit
Net increase of loan from central bank
Net increase of capital borrowed from other financial institution
Cash received from original insurance contract fee
Net cash received from reinsurance business
Insured savings and net increase of investment
Net increase of disposal of transaction financial asset
Cash received from interest, commission charge and commission
Net increase of capital borrowed
Net increase of returned business capital
Write-back of tax received
235,618.93
12,600.72
Other cash received concerning operating activities
21,948,253.46
3,126,083.53
20,867,124.01
3,691,177.83
Subtotal of cash inflow arising from operating activities
2,386,440,229.83
372,971,679.73
1,863,439,264.83
320,953,926.01
Cash paid for purchasing commodities and receiving labor service
2,085,828,647.86
383,325,287.72
1,713,295,011.38
295,952,564.19
Net increase of customer loans and advances
Net increase of deposits in central bank and interbank
Cash paid for original insurance contract compensation
Cash paid for interest, commission charge and commission
Cash paid for bonus ofShenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
11
guarantee slip
Cash paid to/for staff and workers
101,984,825.33
11,276,944.49
87,220,612.85
13,930,549.34
Taxes paid
40,553,881.96
2,446,849.23
41,132,058.80
2,502,447.59
Other cash paid concerning operating activities
90,819,425.47
11,024,791.65
76,906,421.28
14,847,122.05
Subtotal of cash outflow arising from operating activities
2,319,186,780.62
408,073,873.09
1,918,554,104.31
327,232,683.17
Net cash flows arising from operating activities
67,253,449.21
-35,102,193.36
-55,114,839.48
-6,278,757.16
II. Cash flows arising from investing activities:
Cash received from recovering investment
Cash received from investment income
228,443.24
228,443.24
Net cash received from disposal of fixed, intangible and other long-term assets
127,291.00
73,000.00
1,253,650.51
Net cash received from disposal of subsidiaries and other units
Other cash received concerning investing activities
Subtotal of cash inflow from investing activities
127,291.00
73,000.00
1,482,093.75
228,443.24
Cash paid for purchasing fixed, intangible and other long-term assets
14,779,140.94
459,895.00
16,423,384.54
334,010.00
Cash paid for investment
1,350,000.00
Net increase of mortgaged loans
Net cash received from subsidiaries and other units
59,867,260.42
125,819,400.00
Other cash paid concerning investing activities
Subtotal of cash outflow from investing activities
75,996,401.36
126,279,295.00
16,423,384.54
334,010.00
Net cash flows arising from investing activities
-75,869,110.36
-126,206,295.00
-14,941,290.79
-105,566.76
III. Cash flows arising from financing activities
Cash received from absorbing investment
Including: Cash received from absorbing minority shareholders’ investment by subsidiaries
Cash received from loans
170,000,000.00
100,000,000.00
140,000,000.00
80,000,000.00
Cash received from issuing bonds
Other cash received concerning financing activities
103,000,000.00
310,637,849.66
24,293.65
47,200,000.00
Subtotal of cash inflow from financing activities
273,000,000.00
410,637,849.66
140,024,293.65
127,200,000.00Shenzhen Accord Pharmaceutical Co., Ltd. The First Quarterly Report 2009
12
Cash paid for settling debts
60,000,000.00
20,000,000.00
40,022,037.95
10,000,000.00
Cash paid for dividend and profit distributing or interest paying
6,935,403.14
641,686.75
8,021,983.98
467,537.67
Including: Dividend and profit of minority shareholder paid by subsidiaries
Other cash paid concerning financing activities
29,065,294.42
155,020,447.32
823,767.01
94,100,000.00
Subtotal of cash outflow from financing activities
96,000,697.56
175,662,134.07
48,867,788.94
104,567,537.67
Net cash flows arising from financing activities
176,999,302.44
234,975,715.59
91,156,504.71
22,632,462.33
IV. Influence on cash due to fluctuation in exchange rate
-98.26
-98.26
V. Net increase of cash and cash equivalents
168,383,641.29
73,667,227.23
21,100,276.18
16,248,040.15
Add: Balance of cash and cash equivalents at the period -begin
345,259,516.47
62,369,583.65
254,837,411.30
54,841,676.10
VI. Balance of cash and cash equivalents at the period -end
513,643,157.76
136,036,810.88
275,937,687.48
71,089,716.25
4.4 Auditor’ report
Auditor’s opinions: Un-audited
